The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

Park, Hyohun; Hasegawa, Goji; Shima, Toshihide; Fukui, Michiaki; Nakamura, Naoto; Yamaguchi, Kanji; Mitsuyoshi, Hironori; Minami, Masahito; Yasui, Kohichiroh; Itoh, Yoshito; Yoshikawa, Toshikazu; Kitawaki, Jo; Ohta, M.; Obayashi, Hiroshi; Okanoue, Takeshi

doi:10.1016/j.cca.2010.07.012

Cited by 39 publications

(33 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HPI has been reported to promote insulin resistance by inducing chronic inflammation and affecting insulin-regulating gastrointestinal hormones (Aydemir et al 2005), whilst insulin resistance is a key element in NAFLD occurrence (Yoo et al 2013;Gunji et al 2009;Park et al 2010). Moreover, HPI could induce local infiltration of lymphocytes and granulocytes by releasing inflammatory factors such as IL-6, IL-1, and TNF-α, which induces inflammation and aggravates liver damage (Polyzos et al 2013;Park et al 2011).…”

Section: Discussionmentioning

confidence: 99%

Possible association between Helicobacter pylori infection and nonalcoholic fatty liver disease

Chen

Mao

Foster

et al. 2017

Appl. Physiol. Nutr. Metab.

View full text Add to dashboard Cite

Possible association between Helicobacter pylori infection (HPI) and nonalcoholic fatty liver disease (NAFLD) has been proposed by several studies with inconsistent conclusions. Here, we studied the association between HPI and NAFLD at three levels: 1.) Genetic level; 2.) Small molecular level; and 3.) Clinical level. Relation data between diseases, genes, and small molecules were acquired from Pathway Studio ResNet showed that HPI rate in NAFLD group was significantly higher than that in the non-NAFLD group (51.9% vs. 43.6%; p-value= 4.9E-4). Multivariate logistic regression results supported the observations and suggested that HPI served as a risk factor for NAFLD in the experiment data studied (odds ratio: 1.387, p-value = 0.018). Results from this study support the hypothesis that complex biological association may exist between HPI and NAFLD, which partially explain the significant clinical co-incidence in the elderly population of south China.

show abstract

Section: Discussionmentioning

confidence: 99%

Possible association between Helicobacter pylori infection and nonalcoholic fatty liver disease

Chen

Mao

Foster

et al. 2017

Appl. Physiol. Nutr. Metab.

View full text Add to dashboard Cite

show abstract

“…Ezetimibe was opened to the market in the Unites State in 2002. Three Japanese groups reported pilot studies for estimating the effect of ezetimibe and they showed the clinical efficacy of ezetimibe on NAFLD/NASH by evaluating serum biochemical indices and hepatic histology …”

Section: Diagnosismentioning

confidence: 99%

Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Watanabe¹,

Hashimoto²,

Ikejima³

et al. 2015

Hepatology Research

200

192

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various non-invasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary. Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 through January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

“…Ezetimibe was released onto the market in the USA in 2002. Three Japanese groups reported pilot studies for estimating the effect of ezetimibe and they showed the clinical efficacy of ezetimibe against NAFLD/NASH by evaluating serum biochemical indices and hepatic histology [93][94][95].…”

Section: Metformin Cq: Are Biguanides Effective For Patients With Nafmentioning

confidence: 99%

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

et al. 2015

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in industrialized countries worldwide, and has become a serious public health issue not only in Western countries but also in many Asian countries including Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease, which often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma. In turn, a large proportion of NAFLD/NASH is the liver manifestation of metabolic syndrome, suggesting that NAFLD/NASH plays a key role in the pathogenesis of systemic atherosclerotic diseases. Currently, a definite diagnosis of NASH requires liver biopsy, though various noninvasive measures are under development. The mainstays of prevention and treatment of NAFLD/NASH include dietary restriction and exercise; however, pharmacological approaches are often necessary.Currently, vitamin E and thiazolidinedione derivatives are the most evidence-based therapeutic options, although the clinical evidence for long-term efficacy and safety is limited. This practice guideline for NAFLD/NASH, established by the Japanese Society of Gastroenterology in cooperation with The Japan Society of Hepatology, covers lines of clinical evidence reported internationally in the period starting from 1983 to January 2012, and each clinical question was evaluated using the GRADE system. Based on the primary release of the full version in Japanese, this English summary provides the core essentials of this clinical practice guideline comprising the definition, diagnosis, and current therapeutic recommendations for NAFLD/NASH in Japan.

show abstract

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

Cited by 39 publications

References 40 publications

Possible association between Helicobacter pylori infection and nonalcoholic fatty liver disease

Possible association between Helicobacter pylori infection and nonalcoholic fatty liver disease

Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Contact Info

Product

Resources

About